Comparative effect of protein binding on the killing activities of teicoplanin and vancomycin.
about
Population pharmacokinetics and pharmacodynamics of linezolid-induced thrombocytopenia in hospitalized patients.Influence of human serum on pharmacodynamic properties of an investigational glycopeptide, LY333328, and comparator agents against Staphylococcus aureus.Teicoplanin alone or combined with rifampin compared with vancomycin for prophylaxis and treatment of experimental foreign body infection by methicillin-resistant Staphylococcus aureusBactericidal activities of teicoplanin, vancomycin, and gentamicin alone and in combination against Staphylococcus aureus in an in vitro pharmacodynamic model of endocarditis.Vancomycin-resistant enterococci.Penetration of drugs through the blood-cerebrospinal fluid/blood-brain barrier for treatment of central nervous system infections.Prophylaxis with teicoplanin and cefuroxime reduces the rate of prosthetic joint infection after primary arthroplastyPharmacodynamics of ceftazidime administered as continuous infusion or intermittent bolus alone and in combination with single daily-dose amikacin against Pseudomonas aeruginosa in an in vitro infection model.Protein binding and serum bactericidal activities of vancomycin and teicoplanin.Comparative in vitro activities of LY191145, a new glycopeptide, and vancomycin against Staphylococcus aureus and Staphylococcus-infected fibrin clots.Pharmacodynamic evaluation of a new glycopeptide, LY333328, and in vitro activity against Staphylococcus aureus and Enterococcus faeciumActivities of vancomycin and teicoplanin against penicillin-resistant pneumococci in vitro and in vivo and correlation to pharmacokinetic parameters in the mouse peritonitis model.Penetration of teicoplanin into heart valves and subcutaneous and muscle tissues of patients undergoing open-heart surgeryRefining vancomycin protein binding estimates: identification of clinical factors that influence protein binding.Analysis of vancomycin entry into pulmonary lining fluid by bronchoalveolar lavage in critically ill patients.Beta-lactams versus glycopeptides in treatment of subcutaneous abscesses infected with Staphylococcus aureus.Pharmacokinetics and bactericidal rates of daptomycin and vancomycin in intravenous drug abusers being treated for gram-positive endocarditis and bacteremia.Factors impacting unbound vancomycin concentrations in different patient populations.The pharmacokinetic and pharmacodynamic properties of vancomycin.Effect of ester to amide or N-methylamide substitution on bacterial membrane depolarization and antibacterial activity of novel cyclic lipopeptidesThe influence of severe hypoalbuminemia on the half-life of vancomycin in elderly patients with methicillin-resistant Staphylococcus aureus hospital-acquired pneumonia.Therapeutic potential of type A (I) lantibiotics, a group of cationic peptide antibiotics.Effect of ertapenem protein binding on killing of bacteria.Advances in the arsenal of tools available enabling the discovery of novel lantibiotics with therapeutic potential.Clinical laboratory-based assay methodologies may underestimate and increase variability of vancomycin protein binding in hospitalized patients.Effect of human serum on killing activity of vancomycin and teicoplanin against Staphylococcus aureus.Teicoplanin and daptomycin bactericidal activities in the presence of albumin or serum under controlled conditions of pH and ionized calciumIn vitro pharmacodynamic effects of concentration, pH, and growth phase on serum bactericidal activities of daptomycin and vancomycin.Randomized comparison of serum teicoplanin concentrations following daily or alternate daily dosing in healthy adults.A closer look at vancomycin, teicoplanin, and antimicrobial resistance.In vitro bactericidal activity of iclaprim in human plasma.Assessment of oritavancin serum protein binding across species.Impact of human serum albumin on oritavancin in vitro activity against enterococci.Pharmacodynamic activity of the lantibiotic MU1140.Pharmacokinetics of cefpodoxime in plasma and subcutaneous fluid following oral administration of cefpodoxime proxetil in male beagle dogs.Usefulness of teicoplanin for preventing methicillin-resistant Staphylococcus aureus infections in orthopedic surgery.History of antibiotics: from fluoroquinolones to daptomycin (Part 2).Clinical Pharmacokinetics and Pharmacodynamics of Telavancin Compared with the Other Glycopeptides.Surface-stress sensors for rapid and ultrasensitive detection of active free drugs in human serum.
P2860
Q33439246-3C7A96DD-7FB2-4C48-95C8-CED5D2779260Q33697206-FF3227F5-2DF2-4CDB-9810-FDC91803CB58Q33756241-B629ED60-7428-421E-A41A-D15A90BC7495Q33758399-298F8AD7-5366-44E2-92AE-034F80F4B158Q33975592-3796984F-FAC4-4BEA-B1E3-E42FE1310C76Q34142328-F232070A-AC49-4DAA-BBF6-BA49ADB70E27Q35105793-9015DFB4-1BF9-4AAA-96B9-16030D9DE1DCQ35117352-C9B3EF40-69EE-4409-B524-5360C13E0A85Q35117545-639BA16F-C85D-477A-9589-F92E7C92AB8BQ35121233-F2065DD0-E18D-456F-9367-2FA95D1797FDQ35136634-1E9B9289-AED8-4ED5-8B5E-CBD117636EDDQ35138007-FBE5446E-B501-4875-A2E5-59CEE92F83C0Q35139102-00C50193-B7F8-4C0D-B269-07A278AF6E21Q35191519-91B432EB-B68C-4CFB-8049-D4E33CAC3327Q35808723-96A25CDE-68D7-4854-8586-0FE6575B3998Q35820407-87A7707B-8636-43BF-ACA1-AF84217E703AQ35836523-CE6F1A20-3274-4129-B468-CE55201EF883Q36158421-5659BC52-B883-4883-B91E-C9B5E5E28748Q36328971-6EE4F05D-A546-4933-B37A-850F5D121149Q37209021-06A994CB-9918-48AC-8C7C-DB56D16788D0Q37221309-87ED2899-5791-4843-A51A-6C9284FB764DQ37291766-7C9728E8-B772-4CAF-BB27-46D3B5C90781Q37488804-17FFC97A-7071-4D0F-8284-00BB3B002ED8Q38177305-D7EDE2FF-57AB-4797-85D1-20C9710EA4AAQ39397004-87CA7562-115F-462F-B4F5-F9E3DB037B3AQ39400073-199BE034-28FF-41C5-9C73-F41FBA20884AQ39865308-74C9C2A9-D5F9-45E5-AD8F-42605FC7EFD4Q40088863-6AC3B4A6-6854-4E52-84B9-3861CB04F6CDQ40968021-346121D7-5214-4BA7-A157-EA9E549602EBQ41646436-567AD4F4-3CAA-4602-B407-A8D05475F329Q42009215-B7011A73-219E-41F5-BB3C-4DB52521DD69Q42076292-9BDD4685-E821-4CB6-B30A-1C6D43E0DDF9Q43121854-FF3B805A-E192-45B6-B33C-B4717A2E3F7CQ43180417-B660B3D6-B7EA-4257-A2C9-1266CD438905Q44647933-37C7AA12-8F7B-4DAC-8715-7D47C817DC53Q45188856-47BD60EB-9E59-4855-9A83-092E25A80935Q48202873-6AAA9B23-F560-4334-BD5C-359525013106Q50053159-68EE06CF-6735-4B48-A083-D41A101237C1Q53064264-206CFF6B-062D-471B-B71B-81913EEEA5CE
P2860
Comparative effect of protein binding on the killing activities of teicoplanin and vancomycin.
description
1991 nî lūn-bûn
@nan
1991年の論文
@ja
1991年論文
@yue
1991年論文
@zh-hant
1991年論文
@zh-hk
1991年論文
@zh-mo
1991年論文
@zh-tw
1991年论文
@wuu
1991年论文
@zh
1991年论文
@zh-cn
name
Comparative effect of protein ...... of teicoplanin and vancomycin.
@en
type
label
Comparative effect of protein ...... of teicoplanin and vancomycin.
@en
prefLabel
Comparative effect of protein ...... of teicoplanin and vancomycin.
@en
P2093
P2860
P356
P1476
Comparative effect of protein ...... of teicoplanin and vancomycin.
@en
P2093
P2860
P304
P356
10.1128/AAC.35.6.1089
P407
P577
1991-06-01T00:00:00Z